BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shinchi Y, Komohara Y, Yonemitsu K, Sato K, Ohnishi K, Saito Y, Fujiwara Y, Mori T, Shiraishi K, Ikeda K, Suzuki M. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry. Cancer Sci 2019;110:2711-21. [PMID: 31294893 DOI: 10.1111/cas.14128] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Shi Y, Zhao Y, Wang Y. An Inflammatory Response-Related Gene Signature Can Predict the Prognosis and Impact the Immune Status of Lung Adenocarcinoma. Cancers 2022;14:5744. [DOI: 10.3390/cancers14235744] [Reference Citation Analysis]
2 Shinchi Y, Ishizuka S, Komohara Y, Matsubara E, Mito R, Pan C, Yoshii D, Yonemitsu K, Fujiwara Y, Ikeda K, Tamada K, Sakagami T, Suzuki M. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma. Cancer Immunol Immunother 2022;71:2645-61. [PMID: 35352168 DOI: 10.1007/s00262-022-03187-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Matsubara E, Komohara Y, Esumi S, Shinchi Y, Ishizuka S, Mito R, Pan C, Yano H, Kobayashi D, Fujiwara Y, Ikeda K, Sakagami T, Suzuki M. SPP1 Derived from Macrophages Is Associated with a Worse Clinical Course and Chemo-Resistance in Lung Adenocarcinoma. Cancers 2022;14:4374. [DOI: 10.3390/cancers14184374] [Reference Citation Analysis]
4 Yonemitsu K, Pan C, Fujiwara Y, Miyasato Y, Shiota T, Yano H, Hosaka S, Tamada K, Yamamoto Y, Komohara Y. GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer. Sci Rep 2022;12:12007. [PMID: 35835809 DOI: 10.1038/s41598-022-16080-y] [Reference Citation Analysis]
5 Takamochi K, Hara K, Hayashi T, Kohsaka S, Takahashi F, Suehara Y, Shimokawa M, Suzuki K. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.04.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Zou W, Chen L, Mao W, Hu S, Liu Y, Hu C. Identification of Inflammatory Response-Related Gene Signature Associated With Immune Status and Prognosis of Lung Adenocarcinoma. Front Bioeng Biotechnol 2021;9:772206. [PMID: 34881236 DOI: 10.3389/fbioe.2021.772206] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Liang SK, Chien LH, Chang GC, Tsai YH, Su WC, Chen YM, Huang MS, Lin HC, Fang WT, Hung HH, Jiang SS, Chen CY, Chen KY, Chang IS, Hsiung CA, Chen CJ, Yang PC; GELAC Study Group. Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers. Front Oncol 2021;11:753788. [PMID: 34631591 DOI: 10.3389/fonc.2021.753788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Imai H, Kaira K, Hashimoto K, Nitanda H, Taguchi R, Yanagihara A, Umesaki T, Yamaguchi O, Mouri A, Kawasaki T, Yasuda M, Kobayashi K, Sakaguchi H, Kuji I, Kagamu H. Tumor immunity is related to 18 F-FDG uptake in thymic epithelial tumor. Cancer Med 2021. [PMID: 34363337 DOI: 10.1002/cam4.4176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Matsubara E, Komohara Y, Shinchi Y, Mito R, Fujiwara Y, Ikeda K, Shima T, Shimoda M, Kanai Y, Sakagami T, Suzuki M. CD163-positive cancer cells are a predictor of a worse clinical course in lung adenocarcinoma. Pathol Int 2021. [PMID: 34231937 DOI: 10.1111/pin.13144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Gu Q, Li J, Chen Z, Zhang J, Shen H, Miao X, Zhou Y, Xu X, He S. Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma. Front Oncol 2021;11:664032. [PMID: 34178648 DOI: 10.3389/fonc.2021.664032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
11 Kwiecień I, Rutkowska E, Polubiec-Kownacka M, Raniszewska A, Rzepecki P, Domagała-Kulawik J. Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry. Transl Lung Cancer Res 2021;10:1679-89. [PMID: 34012784 DOI: 10.21037/tlcr-20-1103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lin X, Lin K, Lin C, Liu T, Ba M, Tang Y, Wang J, Zhou L, Wang J, Xiao C. Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis. Int Immunopharmacol 2021;91:107280. [PMID: 33370681 DOI: 10.1016/j.intimp.2020.107280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Tian Y, Zhai X, Yan W, Zhu H, Yu J. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC. Cancer Med 2021;10:3-14. [PMID: 33230935 DOI: 10.1002/cam4.3590] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
14 Berardi R, Goteri G, Brunelli A, Pagliaretta S, Paolucci V, Caramanti M, Rinaldi S, Refai M, Pompili C, Morgese F, Torniai M, Marcantognini G, Ricci G, Mazzanti P, Onofri A, Bianchi F, Sabbatini A, Cascinu S. Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach. Expert Opin Ther Targets 2020;24:937-43. [PMID: 32662701 DOI: 10.1080/14728222.2020.1790529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Sun C, Zhang L, Zhang W, Liu Y, Chen B, Zhao S, Li W, Wang L, Ye L, Jia K, Wang H, Wu C, He Y, Zhou C. Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer. Onco Targets Ther 2020;13:6475-83. [PMID: 32753888 DOI: 10.2147/OTT.S252031] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
16 Solinas C, Aiello M, Rozali E, Lambertini M, Willard-Gallo K, Migliori E. Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer? Transl Oncol 2020;13:100811. [PMID: 32622310 DOI: 10.1016/j.tranon.2020.100811] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
17 Mito R, Matsubara E, Komohara Y, Shinchi Y, Sato K, Yoshii D, Ohnishi K, Fujiwara Y, Tomita Y, Ikeda K, Sakagami T, Suzuki M. Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation. Pathol Int 2020;70:287-94. [PMID: 32039532 DOI: 10.1111/pin.12911] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Shinchi Y, Komohara Y, Yonemitsu K, Sato K, Ohnishi K, Saito Y, Fujiwara Y, Mori T, Shiraishi K, Ikeda K, Suzuki M. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry. Cancer Sci 2019;110:2711-21. [PMID: 31294893 DOI: 10.1111/cas.14128] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]